Bolt Biotherapeutics (BOLT) Accounts Payables (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Accounts Payables of $1.7 million for Q1 2026, up 20.3% sequentially from $1.4 million in Q4 2025, and up 13.17% YoY from $1.5 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Accounts Payables (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Accounts Payables for 7 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Accounts Payables rose 13.17% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 13.17% YoY) and the FY2025 annual result came in at $1.4 million, down 4.25% from the prior year.
- Accounts Payables grew to $1.7 million in Q1 2026 per BOLT's latest filing, from $1.4 million in the prior quarter.
- Over five years, Accounts Payables peaked at $4.4 million in Q1 2022 and troughed at $1.4 million in Q4 2025.
- A 5-year average of $2.5 million and a median of $2.2 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 108.3% in 2022, then slumped 59.75% in 2024.
- Over 5 years, Accounts Payables stood at $3.6 million in 2022, then declined by 16.89% to $3.0 million in 2023, then slumped by 49.55% to $1.5 million in 2024, then fell by 4.25% to $1.4 million in 2025, then advanced by 20.3% to $1.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.7 million, $1.4 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | 868,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 868,000.00 |
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.85 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 2.63 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 2.99 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 3.59 Mn |
| Sep 30, 2022 | 3.83 Mn |
| Jun 30, 2022 | 3.36 Mn |
| Mar 31, 2022 | 4.45 Mn |
| Dec 31, 2021 | 3.57 Mn |
| Sep 30, 2021 | 5.16 Mn |